2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
1236
Neoplasms
1040
Carcinoma, Non-Small-Cell Lung
861
Prostatic Neoplasms
692
Colorectal Neoplasms
614
Lung Neoplasms
578
Neoplasm Metastasis
439
Multiple Myeloma
425
Leukemia, Myeloid, Acute
401
Pancreatic Neoplasms
376
Ovarian Neoplasms
364
Melanoma
320
Carcinoma, Hepatocellular
288
Recurrence
276
Squamous Cell Carcinoma of Head and Neck
275
Brain Neoplasms
266
Glioblastoma
247
Head and Neck Neoplasms
244
Stomach Neoplasms
239
Carcinoma, Renal Cell
228
Precursor Cell Lymphoblastic Leukemia-Lymphoma
227
Lymphoma
225
Triple Negative Breast Neoplasms
219
Hematologic Neoplasms
209
Endometrial Neoplasms
209
Urinary Bladder Neoplasms
202
Lymphoma, Non-Hodgkin
197
Uterine Cervical Neoplasms
194
Sarcoma
190
Glioma
190
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
90 days
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled